HB0025 plus chemo shows promising antitumour activity in NSCLC

21 hours ago
HB0025 plus chemo shows promising antitumour activity in NSCLC

The novel bispecific antibody fusion targeting PD-L1 and VEGF HB0025, when added to chemotherapy, demonstrates therapeutic potential in patients with advanced, driver variant–negative non-small cell lung cancer (NSCLC) while having a manageable safety profile, according to a phase II study.

The study included patients with stage IIIB/C or IV nonsquamous or squamous NSCLC without sensitizing EGFR, ALK, or ROS1 alterations, enrolled across 13 hospitals in China.  These patients were randomly assigned to receive intravenous HB0025 at 10 or 20 mg/kg every 3 weeks in addition to chemotherapy (pemetrexed/carboplatin for nonsquamous NSCLC and paclitaxel/carboplatin for squamous NSCLC for up to 6 cycles). All patients received HB0025 maintenance (with pemetrexed for nonsquamous NSCLC) until disease progression or unacceptable toxic effects.

The primary endpoints were safety and investigator-assessed objective response rate (ORR). Secondary endpoints included disease control rate, duration of response, progression-free survival (PFS), and overall survival (OS).

A total of 169 patients were included in the analysis. Of these, 85 were in the nonsquamous cohort (median age 63 years, 30.6 percent female), and 84 were in the squamous cohort (median age 65 years, 7.1 percent female).

Confirmed ORR was 36.4 percent with HB0025 10 mg/kg and 57.1 percent with 20 mg/kg in the nonsquamous cohort and 68.2 percent and 74.2 percent, respectively, in the squamous cohort. Median PFS was 12.52 months overall in the nonsquamous cohort and 14.78 months in the squamous cohort. The 12-month PFS rates overall were 54.3 percent in the nonsquamous cohort and 62.1 percent in the squamous cohort, and the 12-month OS rates overall were 75.8 percent and 85.5 percent, respectively.

Grade ≥3 treatment-related adverse events (AEs) occurred in 65.9 percent of patients in the nonsquamous cohort and 60.7 percent in the squamous cohort, most of which were haematologic toxic effects. Any-grade immune-related AEs related to HB0025 occurred in 23.5 percent in the nonsquamous cohort and 25 percent in the squamous cohort.

JAMA Oncol 2026;doi:10.1001/jamaoncol.2026.4455